Fluorouracil

About

Therapy type: Chemotherapy

Therapy strategy: Thymidylate synthase inhibition

Mappings

NCI Thesaurus: Fluorouracil (coding:ncit:C505)

RxNorm: fluorouracil (coding:rxcui:4492, coding:omop:955632)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
FDA (2) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Irinotecan
FDA (2) Wild type HRAS, Wild type KRAS Colorectal Adenocarcinoma Fluorouracil, Oxaliplatin, Panitumumab
EMA (1) FDA (2) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab
FDA (2) HER2-negative Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab
EMA (1) FDA (8) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab
EMA (1) FDA (4) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
EMA (2) FDA (4) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab
EMA (2) FDA (4) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
EMA (1) FDA (2) CLDN18.2 >= 75%, HER2-negative Adenocarcinoma of the Gastroesophageal Junction Fluorouracil, Oxaliplatin, Zolbetuximab
EMA (2) FDA (2) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin
EMA (1) EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Oxaliplatin
EMA (1) HER2-positive Esophagogastric Adenocarcinoma Cisplatin, Fluorouracil, Trastuzumab
EMA (1) ERBB2 amplification Esophagogastric Adenocarcinoma Cisplatin, Fluorouracil, Trastuzumab
EMA (1) PD-L1 (CPS) >= 1 Head and Neck Squamous Cell Carcinoma Carboplatin, Fluorouracil, Pembrolizumab
EMA (1) PD-L1 (CPS) >= 1 Head and Neck Squamous Cell Carcinoma Cisplatin, Fluorouracil, Pembrolizumab
EMA (1) PD-L1 (CPS) >= 10 Esophageal Adenocarcinoma Cisplatin, Fluorouracil, Pembrolizumab
EMA (1) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Carboplatin, Fluorouracil, Pembrolizumab, Trastuzumab
EMA (1) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab
EMA (1) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Carboplatin, Fluorouracil, Pembrolizumab
EMA (1) PD-L1 >= 1% Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Nivolumab
EMA (1) HER2-negative, PD-L1 (CPS) >= 5 Esophageal Adenocarcinoma Fluorouracil, Nivolumab, Oxaliplatin
EMA (1) HER2-negative, PD-L1 (CPS) >= 5 Adenocarcinoma of the Gastroesophageal Junction Fluorouracil, Nivolumab, Oxaliplatin
EMA (1) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Fluorouracil, Oxaliplatin, Panitumumab
EMA (2) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Fluorouracil, Irinotecan, Panitumumab
EMA (1) PD-L1 (TAP) >= 5% Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Tislelizumab
EMA (1) PD-L1 (TAP) >= 5% Esophageal Squamous Cell Carcinoma Fluorouracil, Oxaliplatin, Tislelizumab
EMA (1) PD-L1 (TAP) >= 5% Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab
FDA (2) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Tislelizumab
FDA (2) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Fluorouracil, Oxaliplatin, Tislelizumab
FDA (2) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Tislelizumab
FDA (2) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Fluorouracil, Oxaliplatin, Tislelizumab
FDA (2) HER2-negative, PD-L1 (TAP) >= 1% Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab
FDA (2) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab
FDA (2) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib, Fluorouracil, Irinotecan
EMA (1) HER2-negative, PD-L1 (CPS) >= 5 Stomach Adenocarcinoma Fluorouracil, Nivolumab, Oxaliplatin